LinkGevity

Executive Summary

LinkGevity is a UK-based biotechnology company pioneering the use of artificial intelligence to discover first-in-class Anti-Necrotic™ drugs that inhibit uncontrolled cell death, a fundamental driver of aging and age-related diseases. Founded in 2019 and currently in Phase 2 development, the company's core platform constructs 'Blueprint Maps' to identify novel therapeutic targets and drug classes for extending human healthspan. By focusing on the necrotic pathway, LinkGevity addresses a previously untapped mechanism in longevity, positioning itself as a unique player in the digital health and AI/machine learning space. The platform's ability to systematically map biological networks could accelerate the discovery of treatments for chronic conditions, potentially transforming the landscape of age-related medicine. LinkGevity's progress to Phase 2 suggests promising preclinical and early clinical data, though specific financial details and valuations remain undisclosed. The company operates in a competitive longevity biotech sector, but its proprietary AI-driven approach offers a differentiated strategy. With a strong scientific foundation and a clear focus on first-in-class therapeutics, LinkGevity has the potential to capture significant value if its lead candidates demonstrate efficacy and safety. However, as a private company with limited public disclosure, near-term visibility is low, and execution risks in clinical development remain. The upcoming catalysts could provide critical inflection points for the company's trajectory and valuation.

Upcoming Catalysts (preview)

• Q4 2026Completion of Phase 2a clinical trial for lead Anti-Necrotic candidate45% success
• H1 2027New partnership or licensing deal for AI platform with large pharma50% success
• Q3 2026Publication of preclinical data on novel target in a high-impact journal70% success